Nrx Pharmaceuticals Inc (NRXP)
$3.02
Market is closed - opens 7 PM, 19 Apr 2024
Insights on Nrx Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 80.4%
Performance
- $3.00$3.22$3.02
0.66%
Downside
Day's Volatility :6.83%
Upside
6.21%
- $2.21$12.00$3.02
26.82%
Downside
52 Weeks Volatility :81.58%
Upside
74.83%
Returns
| Period | Nrx Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -2.34% | -0.7% | 0.0% |
6 Months | 46.67% | 6.6% | 0.0% |
1 Year | -33.65% | 3.7% | -1.5% |
3 Years | -82.76% | 14.0% | -21.8% |
Highlights
Market Capitalization | 42.7M |
Book Value | - $1.42 |
Earnings Per Share (EPS) | -4.0 |
Wall Street Target Price | 31.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -104.08% |
Return On Equity TTM | -682.61% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -27.6M |
Diluted Eps TTM | -4.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.57 |
EPS Estimate Next Year | -0.4 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.5 |
Analyst Recommendation
Buy
88%Buy
11%Hold
0
0%Sell
Based on 9 Wall street analysts offering stock ratings for Nrx Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
- Current
- 1M Ago
- 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 948.68%
Current $3.02
Target $31.67
Technicals Summary
Sell
Neutral
Buy
Nrx Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nrx Pharmaceuticals Inc | -18.83% | 46.67% | -33.65% | -82.76% | -82.76% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nrx Pharmaceuticals Inc | NA | NA | NA | -2.57 | -6.83 | -1.04 | NA | -1.42 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nrx Pharmaceuticals Inc | Buy | $42.7M | -82.76% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Vanguard Group Inc
1.56%AdvisorShares Investments, LLC
0.70%Geode Capital Management, LLC
0.45%BlackRock Inc
0.31%Renaissance Technologies Corp
0.22%Royal Bank of Canada
0.16%
Corporate Announcements
Nrx Pharmaceuticals Inc Earnings
Nrx Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
Organization | Nrx Pharmaceuticals Inc |
Employees | 0 |
CEO | Dr. Jonathan C. Javitt M.D., M.P.H. |
Industry | Healthcare |
